The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S3-S8 , June 2008

Current Strategies for Evaluating, Monitoring, and Treating Type 2 Diabetes Mellitus

  • Jeff Unger, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Jeff Unger, MD, Chino Medical Group Diabetes and Headache Intervention Center, 5475 Walnut Avenue, Chino, California 91710.

References 

  1. American Diabetes Association. Total prevalence of diabetes and pre-diabetes. http://www.diabetes.org/diabetes-statistics/prevalence.jspAccessed October 5, 2006
  2. Unger J. Type 2 diabetes patients need intensive management. Primary Care Network, Primary Issues. 2002;4:1–3
  3. Unger J. Targeting glycemic control in the primary care setting. Female Patient. 2003;28:12–16
  4. Unger J. Intensive management of type 1 diabetes. Emerg Med. 2001;33:30–42
  5. Hiss RG. Barriers to care in non-insulin dependent diabetes mellitus: the Michigan experience. Ann Intern Med. 1996;124:146–148
  6. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  7. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  9. Turner RC, Holman RR UK Prospective Diabetes Study Group. The UK Prospective Diabetes Study. Ann Med. 1996;28:439–444
  10. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  11. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28:59–64
  12. Unger J. Introduction to diabetes. In:  Unger J editors. Diabetes Management in Primary Care. Philadelphia: Lippincott Williams & Wilkins; 2007;p. 1–42
  13. Saydah SH, et al. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–342
  14. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20
  15. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S33–S50
  16. Nathan D. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342–1349
  17. Unger J. Managing mental illness in patients with diabetes. Practical Diabetology. 2006;25:44–53
  18. Colagiuri S, Cull CA, Holman RR UKPDS Group. Are lowering fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: UK Prospective Diabetes Study 61. Diabetes Care. 2002;25:1410–1417
  19. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Medz. 2000;342:381–389
  20. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28:888–894
  21. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963–1972
  22. Solomon DH, Winkelmayer WC. Cardiovascular risk and the thiazolidinediones: déjà vu all over again?. JAMA. 2007;298:1216–1218
  23. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189–1195
  24. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–1188
  25. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosaglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care. 2006;29:54–559
  26. Krentz AJ, Baily CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411
  27. Gallwitz B. Glucagon-like peptide-1 based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol. 2005;4:361–370
  28. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol Metab. 2005;1:22–31
  29. Hood R, Valentine V, Mac S, et al. Use of exenatide in patients with type 2 diabetes. Diabetes Spectrum. 2006;19:181–186
  30. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705
  31. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084
  32. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171–180
  33. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Sitaliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987
  34. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186–193
  35. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitaliptin, in patients with type 2 diabetes inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–745
  36. Ahren B, Gomis R, Standl E, et al. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874–2880
  37. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936–1940
  38. Dejager S, Lebeaut A, Couturier A, et al. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes. 2006;55(suppl 1):29;Abstract 120-OR
  39. Rosenstock J, Baron MA, Schweizer A, et al. Vildagliptin is as effective as rosiglitazone in lowering HbA1c, but without weight gain in drug-naïve patients with type 2 diabetes (T2DM). Diabetes. 2006;55(suppl 1):I33;Abstract 557-P
  40. Rushing PA, Hagan MM, Seeley RJ, et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology. 2000;141:850–853
  41. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34:52–54
  42. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274
  43. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  44. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  45. Garber AJ, Wahlen J, What T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 Study). Diabetes Obes Metab. 2006;8:58–66
  46. Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16 week, randomized, open label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034–2044
  47. Liebl A, Prager R, Kaiser M, et al. Biphasic insulin aspart 30 (BIAsp 30), insulin detemir (IDet) and insulin aspart (IASP) allow patients with type 2 diabetes to reach A1C target: the PREFER study [abstract]. Diabetes. 2006;55(suppl. 1):517–P
  48. Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogs and premixed insulin analogs over human insulins: impact on efficacy and safety. Am J Med. 2008;121(suppl 6A):S9–S19
  49. Tibaldi J. Initiating and intensifying insulin therapy in type 2 diabetes. Am J Med. 2008;121(suppl 6A):S20–S29
  50. Brunton S. Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes treatment. Am J Med. 2008;121(suppl 6A):S35–S41
  51. Rickheim PL, Weaver TW, Flader JL. Assessment of group versus individual diabetes education. Diabetes Care. 2002;25:269–274
  52. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820
  53. Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281:E924–E930
  54. McGiull JB, Cole TG, Nowatzke W, et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a US trial of the GlycoMark assay. Diabetes Care. 2004;8:1859–1865
  55. Kishimoto M, Yamasaki Y, Kubota M, et al. 1,5-anhydro-D-glucitol evaluated daily glycemic excursions in well-controlled NIDDM. Diabetes Care. 1995;18:1156–1159

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00308-2

doi: 10.1016/j.amjmed.2008.03.021

The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S3-S8 , June 2008

Article Tools

* Image Usage & Resolution